ClinicalTrials.gg
Active, not recruitingNCT06657274EARLY-COGN^3Updated Nov 20, 2026

EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069

An interventional study of RICORDO-DTx and Home-based unstructured cognitive stimulation in Mild Cognitive Impairment (MCI), Subjective Cognitive Complaints (SCCs) and Parkinson Disease, sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli. Active, not recruiting at 3 sites in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 175 studies in Cognitive Dysfunction with a site in Italy — 74 open to participants now, 87 under way, 6 of them phase 3. Cognitive Dysfunction · Italy.

Planned enrollment
65th of 111
60 · median 80
Started
2024
with 29 others
No phase
93 of 175
42 open now
Primary completion
2026-11
later than 41 of 86 live
Registered
110th of 175
by date
Lead sponsor
4 of 175
IRCCS Centro San Giovanni di Dio Fatebenefratelli

Among the 175 studies in Cognitive Dysfunction with a site in Italy, this one is the 65th largest by planned enrollment of the 111 interventional ones that give a count, is one of 30 that started in 2024, is one of 93 with no phase, reaches primary completion later than 41 of the 86 other live ones, and was the 110th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

74 of the 175 studies in Cognitive Dysfunction with a site in Italy are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 175 studies in Cognitive Dysfunction with a site in Italy, or all of them as a file.
02

Study summary

The increase in life expectancy in recent decades has led to a large number of people living into old age and an increased risk of developing Chronic Neurological Diseases (CNDs) such as neurodegenerative diseases. A higher cumulative risk of dementia has been largely demonstrated in Mild Cognitive Impairment (MCI) and Subjective Cognitive Complaints (SCCs) subjects and in Parkinson's Disease (PD) patients, as compared to the general population. These disorders result in an impairment of the individual's abilities to perform daily tasks. As their disease progresses, patients become dependent on medical services and on family support. Given the limited effectiveness of pharmacological treatments, non-pharmacological interventions to prevent and treat cognitive deficits and the associated difficulties with activities of daily living in neurodegenerative disease patients have gained attention in recent years and, among these, cognitive training offers a potential approach for dementia prevention and improvement of cognitive function. A critical aspect of cognitive training programs is that the most promising interventions have involved intensive in-person sessions that are unlikely to be cost-effective or feasible for large-scale implementation. Within the framework of non-pharmacological interventions, the use of technology to assist the person at risk and/or with mild dementia at home and to extend rehabilitation services in the treatment of dementia has gradually gained importance. Telerehabilitation technologies allow to provide services remotely in patients' homes, allowing access to health care to patients living in rural settings or with mobility difficulties. In addition, the telerehabilitation modality offers the advantage of providing rehabilitation within the natural environment of the patient's home, making the treatment more realistic and possibly more generalizable to the person's daily life. The present project proposes to test a home-based asynchronous cognitive telerehabilitation program aimed at enhancing the continuum of care for MCI, SCCs and PD, using technology. The proposed study is a single blind randomized controlled trial (RCT) involving subjects with CNDs randomly assigned to one out of two intervention groups: i) the tele@cognitive group, who will receive at-home cognitive telerehabilitation (tele@cognitive treatment); ii) the Active Control Group (ACG), who will receive at-home unstructured cognitive stimulation. The aim of the project will be threefold: [1] to test the short-term and long-term efficacy of tele@cognitive protocol as compared to an unstructured cognitive at-home rehabilitation in the treatment of a cohort of patients with CNDs; [2] to explore the changes induced by tele@cognitive intervention on biomolecular and neurophysiological markers; [3] to explore potential cognitive, neurobiological and neurophysiological predictors of response to tele@cognitive treatment.

Read the detailed description

60 subjects with MCI, SCC, PD will be recruited from IRCCS Istituto Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Fondazione Don Carlo Gnocchi - ONLUS, Milan and IRCCS Centro Neurolesi Bonino Pulejo, Messina.

Patients will include both male and female subjects affected by CND: PD (Hoehn \& Yahr\<3), MCI (with CDR scale≤0.5, MMSE ≥24) and SCC (Subjective Cognitive Complaints).

All patients will undergo treatment sessions of 45 minutes, 3 days a week for 5 weeks:

  • 30 subjects will be assigned to the tele@cognitive group that will receive home-based cognitive telerehabilitation activities with an innovative digital solution for remote rehabilitation of cognitive difficulties according to the digital therapy delivery model;
  • 30 subjects will be assigned to the Active Control Group (ACG) that will receive home-based unstructured cognitive stimulation.

The two groups will be matched for sex, age, education and performance in the MoCA test.

All study participants will be administered a multidimensional assessment by an experienced neuropsychologist at baseline (T0), at post-treatment assessment (T1, 5 weeks from T0) and at 3-month follow-up (T2). In addition, participation in the research involves blood sampling and application of Transcranial Magnetic Stimulation (TMS) before (T0) and after (T1) treatment.

This study is funded by the Italian Ministry of Health under the National Recovery and Resilience Plan (PNRR), Mission 6, Component 2, Investment 2.1, funded by the European Union - NextGenerationEU (project code: PNRR-MCNT2-2023-12377069).

03

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Subjective Cognitive Complaints (SCCs)
  • Parkinson Disease
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PD (Hoehn \& Yahr\<3); MCI (with CDR scale≤0.5, ≥24), and SCC (Subjective Cognitive Complaints);
  • Montreal Cognitive Assessment (MoCA) corrected score ≥17.36
  • Education ≥ 5 years
  • Age eligible for the study: 18≤age≤85
  • Native Italian speakers
  • Absence of marked hearing/visual impairment
  • All of the subjects will have normal or corrected-to-normal vision.
  • Agreement to participate by signing the form
  • Availability of a caregiver/study partner able to support the participant
  • No rehabilitation program in place at the time of enrolment or in the last 3 months before enrolment
  • Stable drug treatment (last 3 months), if any

Exclusion criteria

Exclusion Criteria:

  • Presence of any medical or psychiatric illness that could interfere with completing assessments;
  • Presence of any medical condition representing a to TMS.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    tele@cognitive treatment

    The tele@cognitive treatment group will receive a total of 5 weeks (3 sessions/week, 45 minutes/session) of home-based cognitive rehabilitation activities delivered through a digital telerehabilitation platform.

  • Active comparator
    Active Control Group (ACG)

    The Active Control Group (ACG), will receive at-home unstructured cognitive stimulation for 5 weeks (3 sessions/week, 45 minutes/session).

    Behavioral: Home-based unstructured cognitive stimulation

Interventions

  • DeviceRICORDO-DTx

    Tele@cognitive treatment group will receive a total of 5 weeks (3 sessions/week, 45 minutes/session) of home-based cognitive rehabilitation activities with an innovative digital solution for remote rehabilitation of cognitive difficulties according to digital therapeutics delivery model. Subjects assigned to the tele@cognitive group can access the app RICORDO-DTx through a tablet showing the prescribed rehabilitation activities to be performed. Each cognitive exercise is structured into five levels of difficulty that adaptively increase (algorithm on both subject's performance and perceived difficulty). All data about patient progress and adherence will be collected with this digital solution and will be available to evaluate and monitor the results of rehabilitation.

  • BehavioralHome-based unstructured cognitive stimulation

    Subjects assigned to the home-based unstructured cognitive stimulation will be requested to work on detailed activities for the same duration of the tele@cognitive intervention (3 sessions/week, 45 minutes/session). They will receive, from the therapist, an instructions booklet and a participant diary.

06

What researchers measure

Primary outcomes

  1. Change in global cognition as assessed by Montreal Cognitive Assessment (MoCA)

    Montreal Cognitive Assessment (MoCA) is a screening test for global cognitive functioning. It includes tasks involving several cognitive domains: visuospatial, executive function, naming, selective and sustained attention, language, abstraction, memory and orientation (score range min= 0, max= 30, higher score=better outcome).

    Time frame: Baseline up to 5 weeks and 3 months

  2. Change in long-term episodic verbal memory as assessed by Free and Cued Selective Reminding Test (FCSRT)

    Free and Cued Selective Reminding Test (FCSRT) is a measure of long-term episodic verbal memory. It provides five scores: Immediate Free Recall (IFR, spontaneous recall across three trials; score range min= 0, max= 36), Immediate Total Recall (ITR, total recall across three trials; score range min= 0, max= 36), Delayed Free Recall (DFR, score range min= 0, max= 12), Delayed Total Recall (DTR, score range min= 0, max= 12). Higher scores indicate better performance. Finally, the Index of Sensitivity to Cueing (ISC, score range min= 0, max= 1) reflects the difference between the number of items recalled spontaneously and the number of items recalled with the help of cues. A higher ISC indicates a greater sensitivity to cues.

    Time frame: Baseline up to 5 weeks and 3 months

Secondary outcomes

  1. Change in measure of quality of life as assessed by EQ-5D-5L

    EQ-5D-5L is a measure of health status consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has three response levels (no problems, some problems, unable to/extreme problems). In addition, the questionnaire includes a visual analog scale that records the patient's perception of his or her overall health (score range: min= 0, max= 100, higher score=better outcome).

    Time frame: Baseline up to 5 weeks and 3 months

  2. Change in measure of non-motor experiences of daily living as assessed by MDS-UPDRS scale, part I

    MDS-UPDRS scale, part I (only for PD patients) is a measure of non-motor experiences of daily living consisting of a total of 13 questions (score range min= 0, max= 52, higher score= worse outcome).

    Time frame: Baseline up to 5 weeks and 3 months

  3. Change in measure of motor abilities as assessed by MDS-UPDRS scale, part III

    MDS-UPDRS scale, part III (only for PD patients) is a measure of motor abilities consisting of a total of 18 questions with 33 individual items. Each item has a 0-4 rating, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe (score range: min= 0, max= 132, higher score=worse outcome).

    Time frame: Baseline up to 5 weeks and 3 months

  4. Change in depressive symptoms as assessed by Hamilton Depression Rating Scale (HDRS)

    Hamilton Depression Rating Scale (HDRS) is a measure of severity of depressive symptoms consisting of a total of 21 items (score range min= 0, max= 64, higher score=worse outcome).

    Time frame: Baseline up to 5 weeks and 3 months

  5. Change in anxiety symptoms as assessed by State-Trait Anxiety Inventory (STAI-Y)

    The STAI-Y consisting of two 20-item scales providing separate measures of state and trait anxiety (S-Anxiety and T-Anxiety). Each scale has a score range from a minimum of 20 to a maximum of 80 and a higher score on the scale indicates a worse outcome.

    Time frame: Baseline up to 5 weeks and 3 months

  6. Change in behavior and personality as assessed by Neuropsychiatric Inventory (NPI)

    Neuropsychiatric Inventory (NPI) is used for assessing various neuropsychiatric symptoms. The inventory consists of 12 core domains, each reflecting specific neuropsychiatric symptoms. Each symptom is rated for both frequency and severity. (score range min= 0, max= 144, higher score=worse outcome).

    Time frame: Baseline up to 5 weeks and 3 months

  7. Change in memory complaints as assessed by Everyday Memory Questionnaire (EMQ)

    Everyday Memory Questionnaire (EMQ) is a 20-items questionnaire that evaluate the frequency and impact of memory problems in daily life (score range min= 20, max= 180, higher score=worse outcome).

    Time frame: Baseline up to 5 weeks and 3 months

  8. Change in non-verbal abstract reasoning as assessed by Raven's Coloured Progressive Matrices

    Raven's Coloured Progressive Matrices is a measure of non-verbal abstract reasoning (score range min= 0, max= 36, higher score=better outcome).

    Time frame: Baseline up to 5 weeks and 3 months

  9. Change in measure of attentional abilities as assessed by Trial Making Test (TMT)

    Trial Making Test (TMT, part-A and part-B) is a measure of attentional abilities, visuo-conceptual and visual-motor tracking. TMT-Part A involves visual scanning, number recognition, number sequencing and motor speed. TMT-Part B assesses mental flexibility in managing more than one stimulus at a time and in shifting the course of an ongoing activity. High execution times indicate poor performance (score range: min= n/a, max= no limits).

    Time frame: Baseline up to 5 weeks and 3 months

  10. Change in measure of executive abilities as assessed by Stroop Test

    Stroop Test is a measure of executive abilities, including visual attention, selective attention, cognitive flexibility and inhibitory control of behavior. Two scores are calculated considering the number of errors and the time taken to complete all parts. High execution times and high numbers of errors indicate poor performance.

    Time frame: Baseline up to 5 weeks and 3 months

  11. Change in measure of constructional praxia as assessed by Rey-Osterrieth Complex Figure-Copy

    Rey-Osterrieth Complex Figure-Copy is a measure of constructional praxia (score range min= 0, max= 36, higher score=better outcome).

    Time frame: Baseline up to 5 weeks and 3 months

  12. Change in measure of fluency abilities as assessed by Verbal Fluency (semantic and phonemic)

    Verbal Fluency (semantic and phonemic) is a measure of verbal and semantic fluency abilities, executive functions abilities, lexical store size, lexicon access, and lexical organization (score range min= 0, max= no limits, higher score=better outcome).

    Time frame: Baseline up to 5 weeks and 3 months

  13. Change in measure of nonverbal long-term memory as assessed by Rey-Osterrieth Complex Figure-Recall

    Rey-Osterrieth Complex Figure-Recall is a measure of nonverbal long-term memory (score range min= 0, max= 36, higher score=better outcome).

    Time frame: Baseline up to 5 weeks and 3 months

  14. Change in NFL and Tau

    Neurofilament light chain (NFL) and Tau levels

    Time frame: Baseline up to 5 weeks

  15. Change in Aß1-40, Aß1-42, p-tau-181; p-tau-231, alpha-synuclein

    Aß1-40, Aß1-42, p-tau-181; p-tau-231, alpha-synuclein levels

    Time frame: Baseline up to 5 weeks

  16. Change in GFAP, chemokines and sTREM2

    Glial Fibrillary Acidic Protein (GFAP), chemokines and sTREM2 levels

    Time frame: Baseline up to 5 weeks

  17. Change in Neurogranin and BDNF

    Neurogranin and Brain-Derived Neurotrophic Factor (BDNF) levels

    Time frame: Baseline up to 5 week

  18. Change in plasma EVs

    Size and the concentration of plasma Extracellular Vescicles (EVs)

    Time frame: Baseline up to 5 weeks

  19. Change in rMT

    TMS resting Motor Threshold (rMT)

    Time frame: Baseline up to 5 weeks

  20. Change in MEPs

    TMS Motor Evoked Potentials (MEPs)

    Time frame: Baseline up to 5 weeks

  21. Change in SICI

    TMS Short-interval intracortical inhibition (SICI)

    Time frame: Baseline up to 5 weeks

  22. Change in SAI

    TMS Short-latency afferent inhibition (SAI)

    Time frame: Baseline up to 5 weeks

07

Study locations

3 sites
08

References and documents

Publications

  • Cotelli M, Baglio F, Gobbi E, Campana E, Pagnoni I, Cannarella G, Del Torto A, Rossetto F, Comanducci A, Tartarisco G, Calabro RS, Campisi S, Maione R, Saraceno C, Dognini E, Bellini S, Bortoletto M, Binetti G, Ghidoni R, Manenti R. Smart Digital Solutions for EARLY Treatment of COGNitive Disability (EARLY-COGN;3): A Study Protocol. Brain Sci. 2025 Feb 24;15(3):239. doi: 10.3390/brainsci15030239. PubMed 40149761 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 23 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Aug 2026 → Nov 2026 and completion Aug 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Oct 24, 2024
StartActual
Dec 9, 2024
Primary completionEst.
Nov 30, 2026was Aug 2026
CompletionEst.
Nov 30, 2026was Aug 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 20, 2026
Sites
1 site added, 1 site removed
Show site
  • Fondazione Don Carlo Gnocchi ETS · Milan, Italy
Show 1 removed
  • Fondazione Don Carlo Gnocchi - ONLUS, Milan · Milan, Italy
Nov 20, 2026
Primary completion
Aug 30, 2026→Nov 30, 2026
Nov 20, 2026
Study completion
Aug 30, 2026→Nov 30, 2026
Nov 20, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40149761 ↗
Nov 20, 2026
Sponsor
Collaborators added: Fondazione Don Carlo Gnocchi ETS·IRCCS Centro Neurolesi Bonino Pulejo·Ministry of Health, Italy·Istituto per la Ricerca e l'Innovazione Biomedica; collaborators removed: European Union - NextGenerationEU - PNRR M6C2 - Mission M6 - Component C2 - Investment 2.1 - Valorizzazione e potenziamento della ricerca biomedica del SSN·IRCCS Fondazione Don Carlo Gnocchi, Milano·National Research Council (CNR) - Institute for Biomedical Research and Innovation (IRIB), Messina·IRCCS Centro Neurolesi Bonino Pulejo, Messina
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40149761 ↗
    1 site added, 1 site removed
    Show site
    • Fondazione Don Carlo Gnocchi ETS · Milan, Italy
    Show 1 removed
    • Fondazione Don Carlo Gnocchi - ONLUS, Milan · Milan, Italy
    Primary completion Aug 30, 2026→Nov 30, 2026
    Study completion Aug 30, 2026→Nov 30, 2026
    Sponsor Collaborators added: Fondazione Don Carlo Gnocchi ETS·IRCCS Centro Neurolesi Bonino Pulejo·Ministry of Health, Italy·Istituto per la Ricerca e l'Innovazione Biomedica; collaborators removed: European Union - NextGenerationEU - PNRR M6C2 - Mission M6 - Component C2 - Investment 2.1 - Valorizzazione e potenziamento della ricerca biomedica del SSN·IRCCS Fondazione Don Carlo Gnocchi, Milano·National Research Council (CNR) - Institute for Biomedical Research and Innovation (IRIB), Messina·IRCCS Centro Neurolesi Bonino Pulejo, Messina
    + 4 other changes: verification date, description, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06657274
Lead sponsor
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Collaborators
Fondazione Don Carlo Gnocchi ETS, IRCCS Centro Neurolesi Bonino Pulejo, Ministry of Health, Italy, Istituto per la Ricerca e l'Innovazione Biomedica
Responsible party
Sponsor
First posted
Oct 24, 2024
Start date
Dec 9, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion